Pemetrexed Phase 2

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

5 competitors in Chordoma

#DrugCompanyPhaseTrials

1

Opdivo

Bristol-Myers Squibb

Phase 2

22

Keytruda

Merck & Co.

Phase 2

13

Erbitux

IImclone

Phase 2

24

BL-B01D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

15

ERAS-601

EErasca, Inc.

Phase 2

16

Pemetrexed Phase 2

Eli Lilly

Phase 2

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Completed·Eli Lilly·Phase 2·NCT00370292·19 enrolled

IMT1 trial

Comparing 3 Schedules of Alimta Plus Gemzar

Completed·Eli Lilly·Phase 2·NCT00034606

Chordoma1 trial

Pembrolizumab and Pemetrexed for Progressive Chordoma

Recruiting·SSaint John's Cancer Institute·Phase 2·NCT06794645·21 enrolled

Small Cell Lung Cancer1 trial

Concurrent Pemetrexed, Cisplatin and Radiation Therapy in Patients With Stage IIIA/B Non Small Cell Lung Cancer

Completed·Eli Lilly·Phase 1/2·NCT00529100·49 enrolled

Primary Peritoneal Cancer1 trial

Trial of Pemetrexed and Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer

Completed·Eli Lilly·Phase 1/2·NCT00489359·86 enrolled

Details

Drug Info

Related News